OBJECTIVES: The main rationale for using biosimilar medicines is one of cost saving. The market development for biosimilar drugs will therefore depend on the degree to which cost saving measures are required by nations, medical insurers and individuals and the absolute savings that can be gained by switching from originator brands. The aim of this study is to demonstrate the potential cost savings accrued by switching patients from the originator brand, Remicade® to biosimilar infliximab CT-P13 in the treatment of inflammatory bowel disease in a large acute Irish teaching hospital. METHODS: Throughout September 2016 to May 2017, data were collected on 20 patients that were switched from Remicade® to biosimilar infliximab CT-P13. Cost data for these medicines were obtained using ex-factory prices available from a national pharmaceutical database. Hypothetical biosimilar pricing scenarios using discount rates of 15%, 30% and 45% were applied to the biosimilar infliximab CT-P13 price. These rates are believed to mimic national current commercially sensitive transactions offered by pharmaceutical manufacturers on biosimilar medicines to Irish Hospitals and are corroborated by the literature. The viewpoint of the study was that of the Irish healthcare payer. RESULTS: With respect to the various hypothetical biosimilar pricing scenarios outlined, potential cost savings from switching these 20 patients can range from €76,638 to €180,099. In addition, assuming no applied discount rate to the publically available ex-factory price, switching this cohort of patients to biosimilar infliximab CT-P13 can result in an immediate cost saving of 25% to the Irish healthcare payer. CONCLUSIONS: Cost savings accrued from biosimilar medicine usage is of benefit to all stakeholders: increased access to medicines for patients, more treatment options for prescribers, sustainable healthcare budgets for payers and more business opportunities for manufacturers. Healthcare policymakers are one body that need to do more to increase biosimilar medicine uptake.